



GLAND PHARMA LIMITED

October 17, 2023

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that a meeting of the Board of Directors of Gland Pharma Limited ('the Company') will be held on **Monday, 06th November 2023**, *inter alia*, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023.

Trading Window:

In continuation to our earlier intimation dated September 29, 2023; this is to inform you that the trading window, which was closed from **Sunday, 01st October 2023** in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended; will reopen on **Thursday, 09th November 2023**.

Earnings Call:

Please find enclosed details of the Earnings Call for Investors/Analysts to be held on Monday, November 06, 2023 at 18:30 Hrs (IST).

This is for your information and records.

**Yours truly,
For Gland Pharma Limited**

**Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer**



EARNINGS CONFERENCE CALL

The Company will host Earnings conference call for the second quarter of Financial Year 2024 on **November 6th 2023, at 18:30 hours (IST)**, during which the management team will discuss the performance and take questions. Audio record and Transcript of the conference call will be available at www.glandpharma.com.

Earnings Conference Dial-In Information	
Diamond pass link	Click here to register
Universal Access	+91 22 6280 1516 +91 22 7115 8875
National Toll Free	1 800 120 1221
International Toll-Free Number	USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448

Contact:

Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer
investors@glandpharma.com

Sumanta Bajpayee
Vice President – Corporate Finance & Investor Relations
sumanta.bajpayee@glandpharma.com